# Kimball Electronics account plan

> Kimball Electronics is a Jasper, Indiana EMS and medical CDMO manufacturer with $1,431.4 million of FY2026 sales and about 5,600 employees.

## At a glance

Kimball Electronics (Nasdaq: KE), founded in 1961 and based in Jasper, Indiana, builds electronics and medical products to its customers' designs on a contract basis, combining electronics manufacturing services (EMS) with a contract development and manufacturing organization (CDMO) offer. It serves automotive, medical and industrial customers from plants in the United States, Mexico, Poland, Romania, China, Thailand and, since the July 1, 2026 Helvoet acquisition, the Netherlands and India. In fiscal 2026 (year to June 30, 2026) net sales were $1,431.4 million, down 4%, with operating income of $66.1 million and net income of $28.0 million. It employed about 5,600 people at June 30, 2026, about 1,000 of them in the US. Shareholders were asked at the November 13, 2026 annual meeting to rename the company Kimball Solutions, Inc. (ticker KMBL).

## Business units

- **Automotive** (46% of FY2026 net sales ($656.9 million)): Safety-critical electronic assemblies for chassis control (steering, braking) and body controls, with steering about 70% of the vertical; Nexteer Automotive and ZF are the largest customers. FY2026 sales fell 7% on lower EV demand in North America and the end of a major program, while new steering and braking programs ramped in Poland and Romania. In Q1 FY2027 the vertical grew 4% to $170.5 million.
- **Medical** (29% of FY2026 net sales ($412.8 million)): Medical devices and disposables, drug delivery devices, clean room assembly, sterilization management and precision molded plastics, now marketed under the Kimball Solutions brand; Philips is an 11% customer. It was the only vertical to grow in FY2026 (up 4%) and rose 14% to $115.7 million in Q1 FY2027, including Helvoet sales.
- **Industrial** (25% of FY2026 net sales ($361.7 million)): Electronic assemblies for climate controls, off-highway and commercial equipment, IoT and factory automation, energy and public safety, including commercial-vehicle programs moved from Automotive. FY2026 sales fell 5% on weaker North American residential HVAC, partly offset by smart metering in Europe; Q1 FY2027 sales rose 5% to $104.6 million.
- **Helvoet**: Helvoet Polymer Technologies (Netherlands) and Helvoet Rubber & Plastics Technologies (India), acquired from Hydratec Industries on July 1, 2026, is a CDMO focused on microfluidics, diagnostics and drug delivery. It contributed $12.4 million of revenue in Q1 FY2027 and is led by CEO Eveline Hogenkamp, whose team was given wider medical business development duties.

## Strategic priorities

- **Build a global medical CDMO**: The company aims to establish itself as "a true global medical CDMO platform", combining Helvoet in Europe and India with the new Indianapolis facility. Management expects medical to represent more than one-third of sales in FY2027.
- **Expand the package of value**: Strategy is to move beyond PCBA work into complex system assembly, medical disposables, drug delivery, precision molded plastics and integrated CDMO, with emphasis on medical and pharmaceutical applications.
- **Leverage the global footprint**: Plants in North America, Europe and Asia are positioned for customers seeking geographic diversification and supply-chain resilience; Helvoet adds the Netherlands and India.
- **Rebrand as Kimball Solutions**: The Kimball Solutions brand, rolled out at sites from July 2026, covers the non-electronic portfolio; a company-wide name change to Kimball Solutions, Inc. was put to the November 13, 2026 annual meeting.
- **Grow sales at a 4.4% - 4.7% adjusted margin**: FY2027 guidance is net sales of $1,535 - $1,560 million (high end expected), adjusted operating income of 4.4% - 4.7% of sales and capex of $50 - $60 million.

## Latest results

In Q1 fiscal 2027 (three months to September 30, 2026) net sales rose 7% to $390.8 million from $365.6 million, with 3% organic growth and $12.4 million from Helvoet. Medical grew 14% (9% organic), Industrial 5% and Automotive 4%. Gross margin was flat at 7.9%, while operating income fell to $12.4 million (3.2% of sales) from $14.5 million and net income to $2.6 million ($0.11 per diluted share) from $10.1 million, hit by a 66.1% effective tax rate. Open orders rose 16% to $690 million and the customer count rose to 62. Management reiterated FY2027 guidance, with sales at the high end of $1,535 - $1,560 million.

## Investments and deals

- **Helvoet acquisition**: Bought on July 1, 2026 for about 90.0 million Euro ($103.0 million), the company's largest acquisition to date, funded with cash and credit lines; preliminary goodwill of $44 million and intangibles of $24 million.
- **Indianapolis medical CDMO facility**: A new leased Indianapolis plant replaces the existing medical facility, with production expected to start in December 2026; the CFO put its FY2027 drag at about $6.5 - $7 million.
- **Capital expenditure**: Capex was $51.7 million in FY2026, including the Indianapolis facility, and is guided at $50 - $60 million for FY2027.
- **Share repurchases**: $118.6 million of the $140 million buyback authorisation had been used by September 30, 2026.
- **Divestments and closures**: GES was sold to Averna Test Systems on July 31, 2024 for $18.5 million; the Tampa plant closed at June 30, 2025 and its site was sold on April 22, 2026 for $21.6 million.

## Challenges and risks

- **Customer concentration**: Nexteer Automotive (18%), Philips (11%) and ZF (11%) made about 40% of FY2026 net sales, and automotive customers face cyclical pressure.
- **Automotive demand**: Automotive sales fell 7% in FY2026 on lower North American EV demand, and the 10-K expects "ongoing demand pressure in the automotive vertical" in FY2027.
- **Component supply and inflation**: Memory and electronic components have tightened, with longer lead times and higher costs; costs passed through without margin dilute the operating margin.
- **High tax rate**: The effective tax rate was 47.5% in FY2026 and 66.1% in Q1 FY2027 on dividend withholding taxes; the CFO called the expected low-30s rate too high.
- **Integration and ramp costs**: Helvoet integration, partly debt-funded, and start-up costs at Indianapolis weigh on margins; borrowings rose to $235.7 million after the acquisition.

## What leadership says

> "We are expecting medical to continue to outpace the other two verticals and represent more than one-third of total company sales in the fiscal year" — Ric Phillips, Chief Executive Officer, Q4 and fiscal year 2026 earnings call, August 13, 2026

> "Overall, I'm very pleased to see a return to growth and full year sales trending to the top end of our guidance range." — Ric Phillips, Chief Executive Officer, Q1 fiscal 2027 earnings call, November 5, 2026

> "our excitement for the overall strategic fit and growth opportunities of this new partnership are higher now than ever." — Ric Phillips, Chief Executive Officer, On Helvoet, Q1 fiscal 2027 earnings call, November 5, 2026

> "memory is affecting all of us and electronic components are also tight" — Jana Croom, Chief Financial Officer, Q1 fiscal 2027 earnings call, November 5, 2026


## Where a supplier can help

- **Medical CDMO capacity ramp**: The Indianapolis facility starting production and the Helvoet integration create needs for clean room, molding, sterilization, quality and validation suppliers tied to the medical CDMO priority.
- **Component sourcing and supply resilience**: Tight memory and electronic component supply and rising inventory make sourcing, distribution and supply-chain visibility offers relevant to the component-supply challenge.
- **Cross-selling across the footprint**: Helvoet's team was given AI-driven data-mining tools to find medical opportunities; sales intelligence and business development tools fit the top-line synergy priority.
- **Rebrand to Kimball Solutions**: The company-wide rebrand creates work for branding, marketing, web and corporate-identity providers.
- **Margin and cost programmes**: With an adjusted operating margin target of 4.4% - 4.7% and ramp costs at Indianapolis, automation and productivity offers can be tied to the margin priority.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for the fiscal year ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1606757/000160675726000032/ke-20260630.htm)

Annual report · 2026-08-19

- Kimball Electronics (Jasper, Indiana; Nasdaq: KE), founded in 1961, is a contract manufacturer of durable, high-reliability electronics plus a growing medical CDMO business (medical disposables, drug delivery, precision molded plastics) marketed since 2026 under the Kimball Solutions brand; a name change to Kimball Solutions, Inc. (ticker KMBL) was put to the November 13, 2026 annual meeting.
- FY2026 (year to June 30, 2026): net sales $1,431.4 million, down 4%; gross margin 8.2% (7.0% in FY2025); operating income $66.1 million (4.6% of sales); net income $28.0 million, $1.13 per diluted share (up 64.6%); open orders $643 million, flat.
- Sales by vertical: Automotive 46% ($656.9 million, down 7%), Medical 29% ($412.8 million, up 4%), Industrial 25% ($361.7 million, down 5%). One reportable segment, Business Unit Operations.
- Heavy concentration: Nexteer Automotive 18%, Philips 11% and ZF 11% of net sales; the three together about 40%. The company lost a major automotive program in the past two years and served 50 customers at year end (58 a year earlier).
- Manufacturing in the US, Mexico, Poland, Romania, China, Thailand and, since the July 1, 2026 acquisition of Helvoet (about 90.0 million Euro / $103.0 million, its largest acquisition), the Netherlands and India; about 5,600 employees (about 1,000 in the US).
- Strategy: leverage the global footprint, expand the "package of value" toward complex system assembly, medical disposables, drug delivery and integrated CDMO, and expand markets; a new leased Indianapolis medical CDMO facility will replace the existing one.
- Balance sheet: borrowings $116.6 million, cash $88.9 million, current ratio 2.1, debt-to-equity 0.2; capex $51.7 million; Tampa plant closed and sold (gain $15.0 million).
- Key risks: customer concentration and automotive cyclicality, component shortages and inflation, tariffs (IEEPA refunds partly passed back to customers), Helvoet integration, Indianapolis ramp costs, a 47.5% effective tax rate, reliance on factoring ($315.8 million plus $171.3 million of receivables sold).

### [Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (Q1 fiscal 2027)](https://www.sec.gov/Archives/edgar/data/1606757/000160675726000065/ke-20260930.htm)

Interim report · 2026-11-05

- Q1 FY2027 (three months to September 30, 2026): net sales $390.8 million, up 7% from $365.6 million; foreign exchange added 1%.
- By vertical: Automotive $170.5 million (up 4%), Medical $115.7 million (up 14%), Industrial $104.6 million (up 5%).
- First quarter including Helvoet (acquired July 1, 2026): $12.4 million of revenue and a $(0.3) million net loss; net adjusted purchase price $103.3 million, with $44 million of goodwill and $24 million of intangibles (preliminary).
- Gross margin flat at 7.9%; operating income $12.4 million (3.2% of sales) vs $14.5 million; net income $2.6 million, $0.11 per diluted share, vs $10.1 million.
- Effective tax rate 66.1%, including $3.0 million of withholding tax on a $29.7 million dividend from the China operation used to part-fund Helvoet.
- Open orders $690 million, up 16%; customers rose to 62 (13 new from Helvoet).
- Borrowings rose with the acquisition: net borrowings of $119.2 million in the quarter; debt-to-equity 0.4, current ratio 1.9; operating cash flow $(19.3) million on an inventory build for upcoming program growth.
- Component supply has tightened (longer lead times, higher costs); most increases recovered from customers so far.

### [Kimball Electronics reports Q1 fiscal 2027 results (press release, Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1606757/000160675726000063/exhibit9918k9302026q110q.htm)

Interim report · 2026-11-04

- Q1 FY2027 net sales $390.8 million, up 5% sequentially and 7% year on year; organic growth 3%, with increases in all verticals.
- Medical sales up 14% with 9% organic growth; Automotive $170.5 million (44% of sales), Medical $115.7 million (29%), Industrial $104.6 million (27%).
- Operating income $12.4 million (3.2%); adjusted operating income $16,990 thousand (4.3%) vs $17,534 thousand (4.8%); adjusted EBITDA $27,561 thousand.
- Net income $2,642 thousand ($0.11 per diluted share); adjusted diluted EPS $0.25 vs $0.49.
- Debt $235.7 million, cash $72.8 million, borrowing capacity $198.0 million; cash conversion days 82; $3.1 million spent buying back 127,000 shares.
- FY2027 guidance reiterated, with sales at the high end of $1,535 - $1,560 million, adjusted operating income 4.4% - 4.7% of sales, capex $50 - $60 million.
- CEO Richard D. Phillips: investing in medical growth by integrating Helvoet, ramping Indianapolis and unlocking synergies across the footprint.

### [Q4 and fiscal year 2026 earnings call transcript](https://s28.q4cdn.com/810195283/files/doc_financials/2026/q4/Kimball-Electronics-Q4-26-Webcast-Transcript.pdf)

Executive talk · Ric Phillips, Chief Executive Officer (with Jana Croom, Chief Financial Officer) · 2026-08-13

- Q4 FY2026 call (August 13, 2026): CEO Ric Phillips called FY2026 a "very good finish"; Q4 net sales $371.6 million (down 2%, up 5% sequentially), gross margin 8.9%, adjusted operating income $18.1 million (4.9%).
- Medical was "the headliner": growth in all four quarters and over 10% for the year after normalising FY2025; expected to approach 35% of sales in FY2027.
- Automotive Q4 $170 million (46%), steering about 70% of automotive; decline driven by low EV demand on won programs, not lost programs; Europe new steering and braking programs ramping.
- FY2027 guidance: sales $1.535 - $1.56 billion (7% - 9% growth, 3% - 5% organic, about $60 million from Helvoet), adjusted operating income 4.4% - 4.7%, capex $50 - $60 million.
- New Indianapolis medical facility: production expected from end of calendar 2026; drag of about $6.5 - $7 million in FY2027; about 18 months to ramp new programs.
- CFO Jana Croom: target leverage 1.5x - 2x, could go over 3x briefly for the right deal; buybacks continue; no further acquisition expected this fiscal year.
- Supply chain returning to "golden screw" shortages; working-capital days expected to rise a few days in FY2027.

### [Q1 fiscal 2027 earnings call transcript](https://www.tradingkey.com/news/transcripts/262288907-)

Executive talk · Ric Phillips, Chief Executive Officer (with Jana Croom, Chief Financial Officer) · 2026-11-05

- Q1 FY2027 call (November 5, 2026): CEO Ric Phillips reported a return to growth, with sales of $391 million, up 7% (3% organic, $12.4 million from Helvoet), and full-year sales "trending to the top end" of guidance.
- Medical $116 million, up 14% (9% organic), across drug delivery, respiratory care, patient monitoring, single-use surgical instruments and imaging; CFO expects double-digit core medical growth through the year.
- Automotive $171 million (44%), steering over 70% of it, with a new program in Poland and a transfer in China; North America sluggish on EV demand. Industrial $105 million, up 5%.
- Helvoet integration "on plan and on budget"; Helvoet CEO Eveline Hogenkamp's team given wider medical business development duties and AI-driven data-mining tools.
- Indianapolis medical CDMO production expected to start in December; shareholders to vote on renaming the company Kimball Solutions.
- Open orders up 16% to $690 million; adjusted operating income 4.3%; tax rate 66.1% after repatriating about $30 million of cash; memory and electronic component tightness pressures auto and industrial.

## Questions about Kimball Electronics

### What does Kimball Electronics do?

It is a contract manufacturer offering electronics manufacturing services and medical CDMO solutions, building assemblies and devices for automotive, medical and industrial customers to their designs.

### What is Kimball Electronics' revenue?

Net sales were $1,431.4 million in fiscal 2026 (year to June 30, 2026), down 4%. FY2027 guidance is $1,535 - $1,560 million, with the high end expected.

### How many employees does Kimball Electronics have?

About 5,600 at June 30, 2026, about 1,000 of them in the US and 4,600 abroad.

### Who leads Kimball Electronics?

Richard D. (Ric) Phillips has been CEO since March 2023; Jana T. Croom has been CFO since July 2021.

### What is Kimball Electronics' strategy?

It aims to grow its medical CDMO business through the Helvoet acquisition and the new Indianapolis facility, expand into complex system assembly, drug delivery and molded plastics, and rebrand as Kimball Solutions.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
